Stem Cell Therapy advancements, page-7

A certain other Australian stem-cell company has today rallied hard on receiving a review date with the FDA of its very good trial results in treating acute graft versus host disease (aGVHD), a potentially life-threatening complication of an allogeneic bone marrow transplant which sees something like 50% of recipients with issues. Its very likely to get approval in a scheduled late September date for ruling by the FDA.

An Australian company going commercial with a stem-cell product in America in 4Q 2020, bodes very well for OCC from regulatory, patient, media and other contexts. I've often cited on here, the FDA's acceptance of stem-cells as valuable medical treatments, where they are backed by years of proven treatment and study - who do we know who fulfills that criteria I wonder....?